XBP1 and neoplasm: Targeting this arm using toyocamycin, a small molecule drug inhibiting IRE1α kinase activity and XBP1 splicing, profoundly inhibits both LNCaP and VCaP cell growth in vitro as well as tumor formation in vivo [74].